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Abstract
Background: Differential diagnosis of patients with lung infiltrates remains a challenge. Triggering receptor
expressed on myeloid cells (TREM)-1 is a neutrophil and monocyte receptor up-regulated during infection. The aim
of this study was to evaluate the diagnostic accuracy of TREM-1 and of C-reactive protein (CRP) from patients with
lung infiltrates to discern community acquired lung infections.
Methods: 68 patients admitted to a medical ward with acute respiratory illness were enrolled in the study.
Neutrophil and monocyte TREM-1 expression were measured by flow cytometry, sTREM-1 by an enzyme
immunoassay and C-reactive protein by nephelometry. Clinical pulmonary infection score was recorded.
Results: 34 patients were diagnosed with bacterial community acquired pneumonia (group A) and 34 with non-
bacterial pulmonary disease (group B). Median serum TREM-1 concentration was 102.09 pg/ml in group A and
lower than 15.10 pg/ml (p < 0.0001) in group B. Mean±SE neutrophil TREM-1 expression was 4.67 ± 0.53 MFI in
group A and 2.64 ± 0.25 MFI (p = 0.001) in group B. Monocyte TREM-1 expression was 4.2 ± 0.42 MFI in group A
and 2.64 ± 0.35 MFI (p = 0.007) in group B and mean±SE CRP was 18.03 ± 2 mg/ml in group A and 7.1 ± 1.54
mg/ml (p < 0.001) in group B. A cut-off of 19.53 pg/ml of sTREM-1 with sensitivity 82.6% and specificity 63% to
discriminate between infectious and non-infectious pulmonary infiltrates was found. sTREM-1 at admission greater
than 180 pg/ml was accompanied with unfavourable outcome.
Conclusion: TREM-1 myeloid expression and sTREM-1 are reliable markers of bacterial infection among patients
with pulmonary infiltrates; sTREM-1 is a predictor of final outcome.
Background
Early diagnosis of lung infections remains a challenge.
There is no gold standard for diagnosing microbial
infection as clinical and laboratory signs are neither sen-
sitive nor specific enough, and microbiological studies
often remain negative. The presence of a new infiltrate
on plain chest radiograph is considered indicative for
diagnosing pneumonia, especially when is supported by
clinical and laboratory findings. However it is difficult to
differentiate a chest infiltrate of bacterial origin from a
chest infiltrate of non-bacterial origin solely based on
radiological criteria [1]. The diagnosis of infection is not
always clear in the acute setting in patients with respira-
tory tract disease and a surrogate marker of infection
would be a major benefit in the diagnostic armamentar-
ium. Many inflammatory mediators and acute phase
reactants, like C-reactive protein (CRP) and procalcito-
nin, have been described as reliable markers of infection;
however none are specific enough, since they are also
increased in non-infectious inflammatory conditions [2].
Triggering receptor expressed on myeloid
cells (TREM)-1 is a recently described receptor on
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recognition receptor (PRR) since its activation leads to
the release of pro-inflammatory cytokines, namely of
tumour necrosis factor-alpha (TNFa) and of interleukin
(IL)-8. Although its ligand is still unknown, activation is
mediated by bacteria and fungi [3,4]. A soluble form of
TREM-1, namely sTREM-1, is increased in the bronch-
oalveolar lavage (BAL) of patients with ventilator asso-
ciated pneumonia (VAP) [5,6], and in the serum of
patients with sepsis, with bacterial meningitis and with
acute pancreatitis [7-12]. This same soluble form of
TREM-1 seems to be increased in patients bearing non-
infectious processes like peptic ulcer, inflammatory
bowel disease, viral infections, malignant pleural effu-
sions and chronic obstructive pulmonary disease
(COPD) but also among patients after cardiac surgery
or cardiac arrest. Increase of sTREM-1 seems particular
prominent when the latter non-infectious states are
complicated with systemic inflammatory response syn-
drome (SIRS) without infection [13-19].
Several published studies yielded contradictory
results for the diagnostic and prognostic usefulness of
TREM-1 and of sTREM-1 for infections [5,7,20-22].
The created impression is that more data are necessary
to yield definitive results for its usefulness as a diag-
nostic and prognostic marker of community acquired
pneumonia (CAP).
T h ea i mo ft h ep r e s e n ts t u d yw a st od e f i n ew h e t h e r
expression of TREM-1 on cell membranes of neutro-
phils (nTREM-1), of monocytes (mTREM-1) and serum
sTREM-1 may help in the diagnosis of acute bacterial
infections for patients admitted with a new pulmonary
infiltrate or pleural effusion.
Methods
Study design
In this observation trial, all consecutive admissions to
the Department of Critical Care and Pulmonary Services
on predetermined and randomly selected emergency
duty days were eligible. Inclusion criteria were: i) age
above 16 yrs, ii) written informed consent; iii) acute
respiratory illness and iii) presence of new pulmonary
infiltrates or pleural effusion on chest x-ray or lung
computed tomography. Exclusion criteria were: i)
Human immunodeficiency virus (HIV) infection, ii)
documented extrapulmonary infection, iii) neutropenia;
and iv) oral intake of corticosteroids defined as any
more than 1 mg/kg of prednisone for more than 1
month. The study protocol was approved by the Ethics
Committee of the hospital and written informed consent
was obtained from all patients within the first 12 hrs
after admission.
Clinical, laboratory, and imaging data were recorded
for each patient including: i) clinical presentation; ii)
body temperature, iii) arterial blood gas, iv) peripheral
blood cell counts, v) gram stains and cultures of all bio-
logical fluids obtained (blood, sputum, bronchial secre-
tions, BAL, and pleural fluid); vi) imaging findings, vii)
antigen serology (Legionella spp and Streptococcus pneu-
monia urinary antigen, serological testing for Legionella
pneumophila, Mycoplasma pneumoniae, Chlamydia
pneumoniae) and viii) in-hospital mortality. The severity
of illness was assessed by calculating Acute Physiology
and Chronic Health Evaluation (APACHE) II, Sequential
Organ Failure Assessment (SOFA) and Clinical Pulmon-
ary Infection (CPIS) scores at admission [23].
A diagnosis of community-acquired pneumonia (CAP)
was established in any patient presenting with a combi-
nation of fever, cough and purulent sputum, shortness
of breath, chest pain, and new consolidation on chest
X-ray or computed tomography. The severity of pneu-
monia was assessed the first 24 hours of admission
according to Confusion, Urea nitrogen, Respiratory rate,
Blood pressure (CURB) index. Patients having two or
more criteria were identified to have severe pneumonia
[24]. Sepsis, severe sepsis and septic shock were defined
according to current recommendations [25]. Pneumonia
was considered to be absent when: i) an alternative
cause for pulmonary infiltrate was established (e.g. pul-
monary embolus) and ii) full recovery was achieved
without antimicrobial therapy.
Pulmonary embolism was diagnosed according to cur-
rent recommendations [26]. Lung cancer was ruled out
based on histology and/or cytology specimens. Conges-
tive heart failure was diagnosed according to American
Heart Association [27], and interstitial lung disease
according to American Thoracic Society guidelines [28].
All cases were evaluated by two clinicians blinded to
TREM-1 and sTREM-1 results. Agreement about the
diagnosis was achieved in all cases.
Patients with CAP were classified as having bacterial
respiratory infection (group A). All other patients were
classified as having non-bacterial respiratory disorders
(group B). All patients assigned to group B were subject
to chest computed tomography.
Laboratory investigation
For the measurement of sTREM-1, mTREM-1, nTREM-
1a n dC R P1 0m lo fp e r i p h e r a lv e n o u sb l o o dw e r e
sampled after venipuncture of the antecubitul vein
under sterile conditions on the day of admission and on
days 3 and 7 of hospitalization. Seven ml were centri-
fuged and serum was stored in -80°C until assayed for
sTREM-1. Three ml were collected into EDTA-coated
tubes (Vacutainer, BD) for estimation of nTREM-1 and
mTREM-1 expression. Briefly, red blood cells were lysed
by ammonium chloride. White blood cells were labelled
by phycoerythrin-conjugated anti-TREM-1 monoclonal
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in the dark. nTREM-1 and mTREM-1 expression were
assessed after passage of labelled cells through a flow
cytometer (Epics XL/MSL, Beckman-Coulter Co, Miami
Florida) and expressed as the mean fluorescence inten-
sity (MFI) with gating for neutrophils and for monocytes
by their characteristic FS/SS scattering.
Determination of sTREM-1 was performed in duplicate
by a developmental enzyme-linked immunoabsorbent
assay according to the instructions of the manufacturer
(R&D Inc, Minneapolis, USA). The lower detection limit
and inter-day variation of the assay were 15.1 pg/ml and
5.23% respectively.
Measurement of serum CRP was performed by an
immunoturbidimetric assay on Roche automated clinical
chemistry analyzers and was expressed in mg/ml. CRP
was used as a comparator due to its universal applica-
tion in all studies of evaluation of biomarkers.
Statistical analysis
Asumming that measured parameters between groups A
and B differed by 50%, it was calculated that 30 to 40
patients should be assigned into each group to yield a
difference at the 5% level with 80% power.
Values for nTREM-1, mTREM-1 and CRP are pre-
sented as mean ±SE; those of sTREM-1 are presented as
medians and 95% confidence intervals (CI) or interquar-
tile range (IQR). Comparisons between groups for
nTREM-1, mTREM-1 expression and for CRP were
done by ANOVA, followed by the Tukey’s test for mul-
tiple comparisons. Comparisons of sTREM-1 between
groups were done by Mann-Whitney U test after Bon-
ferroni corrections for multiple comparisons. Compari-
sons of sTREM-1 between consecutive days within one
group were done by Wilcoxon’s signed rank test. Recei-
ver Operator Curves (ROC) were designed to asses sen-
sitivity, specificity, positive and negative predictive
values for the estimated parameters to disclose infec-
tious from non-infectious infiltrates. Patients were
divided into two categories according to serum levels of
sTREM-1 upon admission: those with sTREM-1 below
or equal to 180 pg/ml; and those with serum sTREM-1
greater than 180 pg/ml. This concentration has been
proposed as a threshold defining final prognosis in sep-
tic populations [22,29]. Since CAP is a common cause
of sepsis, this threshold was considered of merit. Survi-
val was assessed by Kaplan-Meier and comparisons were
done by log-rank test. Correlations between severity
scores and measured parameters were done according
to Spearman. Probability values less than 0.05 were con-
sidered statistically significant. All statistics and graphs
were done using the Statistical Package for the Social
Sciences software version 17.0.0 (SPSS Inc, Chicago, IL).
Results
The study flow-chart is shown in Figure 1. Demographic
and clinical data of the patients are summarized in Table
1. Patients suffering from tuberculosis and enrolled in
group B were presented with pleuritis.
Group A (n = 34) consisted of patients with commu-
nity acquired pneumonia (CAP) likely to be caused by
extracellural bacteria. Seventeen had microbiological
evidence of pulmonary infection, with isolation of the
offending pathogens from sputum, blood or BAL sam-
ples (when bronchoscopy was performed). Seventeen
patients were diagnosed with CAP on the basis of typi-
cal clinical and radiological presentation and good
response to antibiotic therapy. Main radiological
Total assessed for eligibility= 102
Group A= 34
(Patients with 
pulmonary infection)
Group B= 34
(Patients without 
pulmonary infection)
Excluded= 34
￿ No chest infiltrate= 32
￿ Urinary tract infection= 1
￿ Deny to consent= 1
Figure 1 Randomization chart of the study.
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left pulmonary infiltrate (nine patients); and bilateral
lung infiltrates (eight patients). Moreover, one patient
presented with left pleural effusion; four patients had
both right pulmonary infiltrate and right pleural effu-
sion; and two patients had both left lung infiltrate and
left pleural effusion.
Group B (n = 34) consisted of patients with non-bac-
terial respiratory disorders. Diagnoses were: lung cancer
(13 patients); pulmonary embolism (six patients); inter-
stitial lung disease (six patients); heart failure (n = 5);
pulmonary tuberculosis (two patients); rheumatoid
pleuritis (one patient); and Q-fever (one patient). Main
radiological findings were: right pulmonary infiltrate (six
patients); left pulmonary infiltrate (three patients); bilat-
eral pulmonary infiltrates (11 patients); right pleural
effusion (four patients); left pleural effusion (one
patient); both right lung infiltrate and right pleural effu-
sion (four patients); both left lung infiltrates and left
pleural effusion (two patients); bilateral pulmonary infil-
trates and left pleural effusion (one patient); and left
pulmonary infiltrate and bilateral pleural effusions (one
patient).
Among patients from group A with CAP nine (n = 9)
died; six patients were admitted to the ICU and three
were not admitted to the ICU due to relatives’ denial.
Mean age of patients not admitted to ICU was 80 years;
the first two patients had a case-history of stroke and
chronic heart failure; the third patient had a case-history
of lung cancer. All three died from severe sepsis and
multiorgan dysfunction syndrome (MODS). Mean age of
patients admitted to ICU was 70 years; two patients had
a case-history of aortic valve stenosis; two patients were
under chronic intake of receiving corticosteroids; the
fifth patient suffered from end-stage renal disease; and
the sixth patient was suffering from hepatic failure due
to alcohol intake. All six patients died from severe sepsis
and multiorgan dysfunction syndrome (MODS). All
patients in the ICU accomplished the clinical and radi-
ological criteria for acute respiratory distress syndrome
(ARDS) and were ventilated with the strategy of low
tidal volume ventilation, according to current guidelines
[30], with volume limited mode ventilation, low tidal
volumes (about 6 ml/kg ideal body weight), a maximum
of 25-30 breaths per minute, high positive end-expira-
tory pressure (PEEP 10 cmH2O) and a goal plateau air-
way pressure < 30 cmH2O. Among patients admitted in
the ICU, two died on the second day post-admission;
one died on the third day post-admission; one on the
seventh day post-admission;o n et h ee i g h t hd a yp o s t -
admission; and one on the twentieth day post admission.
Concentrations of sTREM-1 and of CRP in sera of both
groups and expression of nTREM-1 and mTREM-1 are
given in Table 2. All four parameters were significantly
greater in group A than group B.
ROC of sTREM-1, nTREM-1, m-TREM-1 and CRP to
differentiate whether a chest X-ray infiltrate is due to
CAP or to a non-infectious process is shown in Figure
2. Area under curve (AUC) of sTREM-1 was 0.771 ±
0.068 (95%CI: 0.63 - 0.9, p = 0.001). Sensitivity and spe-
cificity to diagnose between a pulmonary infiltrate of
infectious origin and a pulmonary infiltrate of non-infec-
tious origin were 82.6% and 63% respectively at concen-
trations above 19.53 pg/ml. AUC of nTREM-1 and
mTREM-1 were 0.778 ± 0.063 (95%CI: 0.65 - 0.9, p =
0.001) and 0.712 ± 0.07 (95%CI: 0.56 - 0.86, p = 0.009)
respectively. Sensitivity and specificity to diagnose
between a pulmonary infiltrate of infectious origin and a
pulmonary infiltrate of non-infectious origin were 78.3%
and 58.6% for nTREM-1 above 2.55 MFI. Sensitivity and
Table 1 Demographic and clinical characteristics of 68 patients enrolled in the study
Group A (n = 34) Group B (n = 34) P
Age, (years, mean ± SD) 60.44 ± 3.58 65.83 ± 3.04 < 0.001
Male/female 19/15 21/13 ns
Diagnoses (n) CAP (34) ￿ TB (2) -
￿ Streptococcus pneumoniae (4) ￿ Lung cancer (13)
￿ Staphulococcus aureus (3) ￿ Pulmonary embolism (6)
￿ Haemophilus influenzae (2) ￿ Congestive heart failure (5)
￿ Pseudomonas aeruginosa (2) ￿ Interstitial lung disease (6)
￿ Other (4) ￿ Other (2)
pO2/FiO2 (mean ± SE) 240.18 ± 20.8 314.83 ± 15.9 0.006
SOFA (mean ± SE) 3.11 ± 0.43 1.66 ± 0.18 0.004
APACHE II (mean ± SE) 12.69 ± 1.06 9.4 ± 1.09 0.037
CPIS (mean ±SE) 5.38 ± 0.23 2.06 ± 0.25 < 0.001
Mortality [n (%)] 9 (26) 2 (5.8)
White blood cells
(mean ±SE)
14172.4 ± 1314.7 10470 ± 874.2 0.023
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Page 4 of 10Table 2 Concentrations of soluble triggering receptor expressed on myeloid cells-1 (sTREM-1) and of C-reactive
protein (CRP) in the sera and expression of TREM-1 on neutrophils and on monocytes of 68 patients with pulmonary
infiltrates
§
Survivors Non-Survivors p Group A Group B p
sTREM-1 (pg/ml, median-IQR)
Day1 28.13 (95.00) 189.61 (204.99) 0.028 102.09 (227.21) < 15.10 (31.04) < 0.0001
Day3 < 15.10 (39.45) 122.80 (231.05) 0.065 28.12 (263.74) < 15.10 (21.10) 0.010
Day 7 < 15.10 (35.60) 52.30 (225.81) 0.055 12.96 (202.89) < 15.10 (18.80) 0.022
TREM-1 on neutrophils (MFI, mean ± SE)
Day1 3.55 ± 0.53 4.18 ± 1.07 NS* 4.67 ± 0.53 2.64 ± 0.25 0.001
Day3 2.26 ± 0.25 3.40 ± 1.10 NS 3.14 ± 0.37 1.57 ± 0.20 NS
Day 7 1.46 ± 0.31 2.34 ± 0.95 NS 1.20 ± 0.37 1.60 ± 0.43 NS
TREM-1 on monocytes (MFI, mean ± SE)
Day1 3.24 ± 0.31 4.51 ± 0.91 NS 4.2 ± 0.42 2.64 ± 0.35 0.007
Day3 2.02 ± 0.33 3.42 ± 0.57 NS 1.50 ± 0.20 2.20 ± 0.43 0.001
Day 7 2.35 ± 0.25 4.25 ± 1.45 NS 1.76 ± 0.20 3.21 ± 0.43 0.003
CRP (mg/dl, mean ± SE)
Day1 11.6 ± 1.5 16.6 ± 3.8 NS 18.03 ± 2 7.1 ± 1.5 < 0.001
Day3 9.4 ± 1.4 12.3 ± 2.7 NS 12.2 ± 2.0 7.1 ± 1.5 0.05
Day 7 6.4 ± 1.1 9.7 ± 3.5 NS 7.2 ± 1.5 6.2 ± 1.6 NS
*NS: non significant
§Patients are divided into two groups; survivors and non-survivors; and into those with community-acquired pneumonia (group A) and into those with an
infiltrate of non-infectious origin (group B).
Figure 2 Receiver operator curves (ROC) of serum sTREM-1, of TREM-1 expressed on neutrophils (nTREM-1), of TREM-1 expressed on
monocytes (mTREM-1) and of serum CRP to discriminate between a pulmonary infiltrate of bacterial origin from a pulmonary
infiltrate of non-bacterial origin.
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infectious origin and a pulmonary infiltrate of non-infec-
tious origin were 82.6% and 75.9% respectively for
mTREM-1 above 3.05 MFI. AUC of CRP was 0.789 ±
0.065(95%CI: 0.66 - 0.9, p < 0.001). Sensitivity and speci-
ficity to diagnose between a pulmonary infiltrate of
infectious origin and a pulmonary infiltrate of non-infec-
tious origin were 78% and 76% respectively at concen-
trations above 8.7 mg/ml.
Positive correlations were found between APACHE II
scores and expression of TREM-1 on monocytes on day
1( r s: +0.363, p: 0.010); and between APACHE II scores
and sTREM-1 on day 1 (rs: +0.262, p: 0.043). No signifi-
cant correlations were found between APACHE II
scores and expression of TREM-1 on neutrophils on day
1 as well as between SOFA scores and any of the mea-
sured parameters on day 1.
Correlations between serum levels of sTREM-1 and
CRP and expression of TREM-1 on monocytes and neu-
trophils in relation to the identified causative pathogen
of CAP are shown in Figure 3. Serum levels of sTREM-
1 were greater among patients with CAP caused by
Gram (+) cocci and Haemophilus influenzae than
among patients with CAP caused by other pathogens.
Death occurred in three out of 17 patients were no
pathogen was defined (17.6%); in nil out of three
patients infected by atypical pathogens (0%); in three
out of seven patients (42.9%) infected by Gram-negative
bacteria; and in three out of nine patients (33.3%)
infected by Gram-positive cocci or H. influenzae (p:
0.034 between grouping according to pathogen). Survival
of patients with sTREM-1 on day 1 below or equal to
180 pg/ml was prolonged compared with patients with
sTREM-1 on day 1 above 180 pg/ml (Figure 4).
Figure 3 Concentrations of sTREM-1 and of CRP in serum and expression of TREM-1 on monocytes and on neutrophils on the first
day of acute respiratory illness of patients with new consolidation in chest X-ray. Results are given as box plots for sTREM-1 and as
means ± SE for the other parameters. ND: not defined. Statistically significant comparisons are indicated.
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expression of nTREM- and of mTREM-1 on days 3 and
7 are shown in Table 2. Estimated parameters were
greater in group A than in group B. Median (IQR)
sTREM-1 of survivors of group A was 90.52 (398.04)
pg/ml on day 1; it was decreased to 17.20 (257.73) pg/
ml on day 3 (p: 0.012 compared with day 1); and it was
decreased to 10.40 (174.69) pg/ml on day 7 (p: 0.007
compared with day 1). Median (IQR) sTREM-1 of non-
survivors of group A was 189.61 (186.73) pg/ml on day
1; it was unchanged on day 3 [144.07 (258.10) pg/ml; p:
NS compared with day 1]; and it was unchanged on day
7 [59.03 (272.96) pg/ml, p: NS compared with day 1].
Discussion
The results of the present study indicate that TREM-1
can be used as marker of bacterial infection in patients
with lung infiltrates. sTREM-1, nTREM-1, mTREM-1
and CRP were comparable to their discriminating ability
between a pulmonary infiltrate of infectious origin and a
pulmonary infiltrate of non-infectious origin. sTREM-1
levels were decreased within the first 48 hours in
patients with CAP with favourable outcome probably
after the initiation of appropriate therapy followed by
improvement of clinical symptoms. Finally, sTREM-1
levels above 180 pg/ml were an accurate independent
predictor of in-hospital mortality from CAP.
Discrimination of the infectious or non-infectious ori-
gin of a pulmonary infiltrate remains an everyday clini-
cal problem. CPIS was introduced for that purpose
helping considerable in cases of ventilator-associated
pneumonia (VAP) [23]. TREM-1 is a surface receptor
on cells of the myeloid lineage. Activation of TREM-1
leads to the production of pro-inflammatory cytokines
[9,31,32]. Binding of its ligand is possibly linked to the
activation of several transcription complexes that syner-
gize with NF-B in order to elicit transcription of genes
of pro-inflammatory cytokines [8]. sTREM-1 is the solu-
ble counterpart of TREM-1 and it is probably shed in
the systemic circulation from cell membranes of neutro-
phils and monocytes [7,33,34]. The physiologic role of
sTREM-1 remains under question despite data support
a probable anti-inflammatory role [31,35].
TREM-1 has been studied in patients with pneumonia,
especially VAP [5,21,36-38]. Few data are available on
the diagnostic role of TREM-1 and of sTREM-1 in
patients with lung infiltrates. Our data are in agreement
with observations from the study by Phua [36]. Their
proposed sTREM-1 cut-off point was 163 ng/ml, which
is different than the one we found. This may be result
Figure 4 Survival of patients with acute respiratory illness and with new consolidation in chest X-ray in relation to serum
concentration of sTREM-1 on day 1.
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used being Western blotting.
The results of our study are in contrast to those of
another study [37] that did not disclose any difference
in nTREM-1 expression between patients with and with-
out a bacterial lung infection probably due to the small
number of patients included in that former study. El
Sohl et al [38] reported elevated alveolar levels of
sTREM-1 in pulmonary aspiration syndromes, but not
in serum. However, serial plasma sTREM-1 levels were
not obtained and the possibility that plasma levels might
rise on subsequent days cannot be excluded.
Two recent studies [39,40] evaluated the diagnostic
role of CPIS and of sTREM-1 in BAL fluid from patients
with bilateral lung infiltrates in the intensive care unit
(ICU). These studies reported controversial results.
However authors did not measure sTREM-1 in serum
on consecutive days.
The reported results of the present study are the first
to our knowledge that evaluate the diagnostic value of
TREM-1 among patients with lung infiltrates to discri-
minate CAP. They also disclose a relationship between
levels of circulating sTREM-1 and causative pathogens.
More precisely, infections caused by Streptococcus pneu-
moniae, Sthaphylococcus aureus and Haemophilus influ-
enzae were accompanied by greater levels of sTREM-1
and by greater expression of TREM-1 on neutrophils
than infections caused by other pathogens. Although it
may be hypothesized that Gram-positive cocci and
H. influenzae are strong inducers of TREM-1 expres-
sion, it should be emphasized that TREM-1 is one PRR,
the exact agonist of which remains to be found [29,31].
A former study of our group [29] and another by
Gibot et al [22] in heterogeneous populations of patients
with severe sepsis of diverse aetiology investigated the
role of early assessment of sTREM-1 as a determinant
of final outcome. Results revealed that concentrations
greater than 180 pg/ml are accompanied by survival
benefit. The exactly opposing finding is reported here.
This discrepancy may be explained by the enrolment of
more homogeneous populations of patients, compared
to these former studies [22,29], all suffering with CAP.
Our study presents two main limitations: a) no docu-
mented cases of CAP by Legionella pneumophila, Myco-
plasma pneumoniae, protozoa or parasites were enrolled
in group A; b) mortality in the CAP patient group was
high probably due to the existence of severe co-morbid
conditions.
Conclusions
In conclusion, the presented results indicate that serum
sTREM-1 and expression of TREM-1 on neutrophils
and monocytes may serve as markers of CAP in patients
with pulmonary infiltrates. Concentrations of sTREM-1
in serum are particularly increased in CAP caused by
Gram-positive cocci and Haemophilus species. The real
clinical value of sTREM-1 assay comes when TREM-1
levels are low, allowing the clinician to withhold empiric
antibiotics until culture results are available, and thus
eliminating unnecessary antibiotic exposure to the
patient. And finally, early serum levels of sTREM-1
greater than 180 pg/ml in CAP are associated with unfa-
vourable prognosis.
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